A Comparative Study of Mass Spectrometry and Affinity-based Platforms

Harnessing the information present in the plasma proteome requires robust large-scale analytical techniques. Our latest white paper gives you a better understanding of two leading technology platforms for plasma proteomics: Biognosys’ TrueDiscovery™ and Olink Explore. We compared the ability of both platforms to analyze the plasma proteome in prostate cancer.

Each approach has unique strengths and complements the other in capturing the diversity of the proteome and uncovering actionable #biomarkers. Our TrueDiscovery platform unleashes the full power of mass spectrometry to find the deepest biological insights in a truly unbiased manner.